In ovarian cancer, PARP7 MARylates α-tubulin, promoting cancer cell migration; consequently, PARP7 inhibition reduces cell growth and motility in ovarian, cervical and kidney cancer cells (Palavalli Parsons et al., 2021). Here, TIPARP is linked to ovarian carcinoma.